NDA 205422 · Otsuka
Rexulti
Brexpiprazole · Oral · Atypical Antipsychotic
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jul 10, 2015
Approved uses
7
Original approval plus efficacy supplements
Registered trials
81
50 Phase 3, 7 recruiting
FAERS reports
16,890
7,192 serious, 1,179 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease. ( 5.1 ) Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of REXULTI have not been established in pediatric patients with...
What it is approved for
From the label in effect Jun 2, 2026.
REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3) ] . REXULTI is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 , 14.1 ) Treatment of schizophrenia in adults and pediatric patients ages 13 years and older ( 1 , 14.2 ) Treatment of agitation associated with dementia due to Alzheimer's disease ( 1 , 14.3 ) Limitations of Use : REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease ( 1 )
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 9, 2025 Supplement 14 · Efficacy LetterLabel
- May 7, 2024 Supplement 11 · Efficacy · priority review LetterLabelMedication Guide
- May 10, 2023 Supplement 9 · Efficacy · priority review LabelLetterReview
- Dec 27, 2021 Supplement 7 · Efficacy · priority review LetterLabel
- Sep 23, 2016 Supplement 1 · Efficacy LetterLabel
- Jul 10, 2015 Original approval · Efficacy Label
- Jul 10, 2015 Original approval · Type 1 - New Molecular Entity LabelReviewLetter
6 products under this application
- REXULTI · BREXPIPRAZOLE 3MG · TABLET, ORAL · Prescription · TE AB
- REXULTI · BREXPIPRAZOLE 1MG · TABLET, ORAL · Prescription · TE AB
- REXULTI · BREXPIPRAZOLE 0.25MG · TABLET, ORAL · Prescription · TE AB
- REXULTI · BREXPIPRAZOLE 4MG · TABLET, ORAL · Prescription · TE AB
- REXULTI · BREXPIPRAZOLE 2MG · TABLET, ORAL · Prescription · TE AB
- REXULTI · BREXPIPRAZOLE 0.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Brexpiprazole" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01727726 · 2,182 participants · Start Dec 2012 · Primary completion Oct 17, 2016
Drug: Brexpiprazole; Seroquel XR and 1 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 76 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360632 · 1,539 participants · Start Jun 2011 · Primary completion Aug 2013
Drug: OPC-34712 + ADT; Placebo + ADT and 1 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Costa Mesa, California; Glendale, California · 71 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
- Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00797966 · 850 participants · Start May 2009 · Primary completion Jun 2010
Drug: OPC-34712; Placebo and 1 more · For: Major Depressive Disorder
Sites: Arcadia, California; Beverly Hills, California; Escondido, California · 50 sites in all
- Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious DistressPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02196506 · 837 participants · Start Jul 2014 · Primary completion Apr 2016
Drug: Placebo + ADT; Brexpiprazole +ADT · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Beverly Hills, California; Denver, Colorado · 47 sites in all
- Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360645 · 826 participants · Start Jul 2011 · Primary completion May 2013
Drug: OPC-34712 + ADT; Placebo + ADT and 1 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Arcadia, California; Beverly Hills, California; Fresno, California · 57 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight increased1,712
- product use in unapproved indication1,400
- off label use1,172
- drug ineffective984
- akathisia880
- tremor662
- anxiety629
- death603
- tardive dyskinesia603
- depression598
- suicidal ideation595
- product use issue516
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 229 |
| 2016 | 2,107 |
| 2017 | 1,551 |
| 2018 | 1,417 |
| 2019 | 1,701 |
| 2020 | 1,423 |
| 2021 | 1,433 |
| 2022 | 1,328 |
| 2023 | 1,446 |
| 2024 | 1,781 |
| 2025 | 1,372 |
| 2026 | 1,100 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rexulti (Brexpiprazole)
2024 spending
$861M
Beneficiaries
94,695
598,492 claims
Per beneficiary
$9,096
$49.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $358,159,997 |
| 2021 | $403,387,369 |
| 2022 | $490,498,963 |
| 2023 | $630,013,840 |
| 2024 | $861,392,150 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, et al. · Lancet Psychiatry 2020 · Comparative Study, Network Meta-Analysis
- Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.
Nakamura Y, Adachi J, Hirota N, et al. · Alzheimers Dement 2024 · Randomized Controlled Trial, Multicenter Study
- Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.
Wu H, Siafis S, Hamza T, et al. · Schizophr Bull 2022 · Meta-Analysis
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.